Forte Biosciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.851
- Today's High:
- $0.91
- Open Price:
- $0.851
- 52W Low:
- $0.898
- 52W High:
- $1.54
- Prev. Close:
- $0.858
- Volume:
- 23225
Company Statistics
- Market Cap.:
- $21.05 million
- Book Value:
- 1.568
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -29.22%
- Return on Equity TTM:
- -49.5%
Company Profile
Forte Biosciences Inc had its IPO on 2017-04-13 under the ticker symbol FBRX.
The company operates in the Healthcare sector and Biotechnology industry. Forte Biosciences Inc has a staff strength of 7 employees.
Stock update
Shares of Forte Biosciences Inc opened at $0.85 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.85 - $0.91, and closed at $0.86.
This is a +0.47% increase from the previous day's closing price.
A total volume of 23,225 shares were traded at the close of the day’s session.
In the last one week, shares of Forte Biosciences Inc have increased by +3.86%.
Forte Biosciences Inc's Key Ratios
Forte Biosciences Inc has a market cap of $21.05 million, indicating a price to book ratio of 0.4854 and a price to sales ratio of 0.
In the last 12-months Forte Biosciences Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-13860000. The EBITDA ratio measures Forte Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Forte Biosciences Inc’s operating margin was 0% while its return on assets stood at -29.22% with a return of equity of -49.5%.
In Q1, Forte Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Forte Biosciences Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.95 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Forte Biosciences Inc’s profitability.
Forte Biosciences Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.8977. Its price to sales ratio in the trailing 12-months stood at 0.
Forte Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $36.71 million
- Total Liabilities
- $3.76 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Forte Biosciences Inc ended 2024 with $36.71 million in total assets and $0 in total liabilities. Its intangible assets were valued at $36.71 million while shareholder equity stood at $32.95 million.
Forte Biosciences Inc ended 2024 with $0 in deferred long-term liabilities, $3.76 million in other current liabilities, 21000.00 in common stock, $-93797000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $35.90 million and cash and short-term investments were $35.90 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Forte Biosciences Inc’s total current assets stands at $36.27 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.34 million and inventory worth $0.
In 2024, Forte Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Forte Biosciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.86
- 52-Week High
- $1.54
- 52-Week Low
- $0.898
- Analyst Target Price
- $3.5
Forte Biosciences Inc stock is currently trading at $0.86 per share. It touched a 52-week high of $1.54 and a 52-week low of $1.54. Analysts tracking the stock have a 12-month average target price of $3.5.
Its 50-day moving average was $0.92 and 200-day moving average was $0.99 The short ratio stood at 1.21 indicating a short percent outstanding of 0%.
Around 1856.3% of the company’s stock are held by insiders while 3775% are held by institutions.
Frequently Asked Questions About Forte Biosciences Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.